Select Topic:
Browse by Series:

Antiandrogen Monotherapy for mCRPC

Panelists: Philippa J. Cheetham, MD, Stonybrook University;Raoul S. Concepcion, MD, Urology Associates, PC; Kenneth M. Kernen, MD, Michigan Urology;
Published: Tuesday, Aug 05, 2014

For High-Definition, Click
A seminal paper published by Charles Huggins, MD, in 1941 on castration and the effects of androgen deprivation on prostate cancer has continued to influence the treatment of prostate cancer to this day. Oliver Sartor, MD, notes that the use of LHRH analogues in the treatment of prostate cancer has been a major advance, because with LHRH therapy, men can avoid castration while still benefiting from androgen deprivation.

Although the older anti-androgens, such as bicalutamide and flutamide, may have benefits in non-metastatic disease, they do not produce the level of androgen deprivation necessary to control metastatic disease, Sartor states. He comments that newer antiandrogen agents are superior to older agents, and newer agents have advantages, such as libido- and bone-sparing effects; however, a disadvantage is that the newer agents are associated with gynecomastia. Clinicians may consider anti-androgen monotherapy with a newer agent for patients with metastatic disease.

Kenneth Kernen, MD remarks that the use of diethylstilbestrol (DES) has declined due to the thromboembolic risk associated with its use and the introduction of newer agents. Neal Shore, MD, comments that increased estradiol levels can have beneficial effects. In the United Kingdom, transdermal estrogen is currently being evaluated in clinical trials. 

Slider Left
Slider Right
For High-Definition, Click
A seminal paper published by Charles Huggins, MD, in 1941 on castration and the effects of androgen deprivation on prostate cancer has continued to influence the treatment of prostate cancer to this day. Oliver Sartor, MD, notes that the use of LHRH analogues in the treatment of prostate cancer has been a major advance, because with LHRH therapy, men can avoid castration while still benefiting from androgen deprivation.

Although the older anti-androgens, such as bicalutamide and flutamide, may have benefits in non-metastatic disease, they do not produce the level of androgen deprivation necessary to control metastatic disease, Sartor states. He comments that newer antiandrogen agents are superior to older agents, and newer agents have advantages, such as libido- and bone-sparing effects; however, a disadvantage is that the newer agents are associated with gynecomastia. Clinicians may consider anti-androgen monotherapy with a newer agent for patients with metastatic disease.

Kenneth Kernen, MD remarks that the use of diethylstilbestrol (DES) has declined due to the thromboembolic risk associated with its use and the introduction of newer agents. Neal Shore, MD, comments that increased estradiol levels can have beneficial effects. In the United Kingdom, transdermal estrogen is currently being evaluated in clinical trials. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x